PhotoCure Pursues Niche Cancer Market In Wake Of Skin Lesion Approval
This article was originally published in The Gray Sheet
Executive Summary
PhotoCure will target an additional 1 mil. cases per year in the U.S. with approval of a basal cell carcinoma indication for Metvix therapy, expected by year-end, the firm says